Structural studies of the AMBRA1 and D-type cyclins have laid the foundation for the development of small molecules targeting the E3 ligase–receptor–substrate complex and provide the potential treatment for diseases characterized by dysregulated cyclin activity, such as cancer. The gene discussed is AMBRA1; the disease is cancer.